On November 17, the world’s largest medical exhibition, MEDICA 2025, grandly opened in Düsseldorf, Germany. WBL Medical Group made its debut in Europe with a complete brand identity, showcasing the latest generation of the LIPUS micro-energy medical system at booth Hall 15–A24-1, quickly becoming the highlight of the first day of the exhibition.
On the opening day, WBL's booth was bustling with visitors, attracting numerous physicians and medical distributors from Europe, the Middle East, South America, Eastern Europe, and Southeast Asia. Many came to exchange ideas and inquire about the technology, with frequent discussions and negotiations taking place.
WBL was awarded the IDEA Award for its LIPUS technology, a recognition that not only acknowledges its innovative achievements in the medical technology field but also highlights its exceptional R&D capabilities. In addition, WBL was featured on CCTV12’s Science and Technology China program, becoming the first medical industry company to appear on the show, further cementing its leadership position in the industry. These achievements, like dazzling medals, have made WBL increasingly prominent on the global medical stage and have raised global expectations for its future development.
Urology Field: LIPUS Introduces Systematic Approach to Europe, Sparking Strong Interest
This year, WBL introduced the LIPUS technology and its complete treatment logic to the European market for the first time, which quickly attracted the attention of many professionals. Urologists and male medicine physicians from Switzerland, Italy, Greece, Spain, Poland, and Croatia actively visited WBL’s booth.
Several urologists lingered at the booth for 20 to 40 minutes, asking detailed questions about the non-invasive micro-energy treatment principles, the application of LIPUS in ED (erectile dysfunction), CPPS (chronic prostatitis pain syndrome), urinary incontinence, testosterone treatment, clinical logic, treatment protocols, the consumables business model, and the timeline for CE certification in 2025.
Many doctors, seeing the complete LIPUS system for the first time at a European medical exhibition, commented: "This is a treatment option we have been lacking for a long time."
Regenerative Medicine & PRP Field: Strong Collaborative Intentions from Multiple Countries
Greece: PRP Team Highly Recognizes LIPUS, Urgent Desire for Collaboration
A well-known PRP team from Greece (a father-daughter medical team) showed strong interest in LIPUS after the presentation. They highly recognized the synergistic effect of PRP and micro-energy treatment and the commercial potential of multi-modal treatment combinations. They also pointed out that there is existing clinical demand within the Greek urology community and expressed interest in collaborating with leading hospitals to conduct demonstrations.
Brazil: High Demand, Active Pursuit of Demonstration Cooperation
A large medical company from Brazil, which has an extensive network of urology physicians, responded enthusiastically to the integration logic of LIPUS + PRP. They mentioned that Brazilian patients are highly receptive to PRP, functional medicine, and non-invasive therapies. The combination of LIPUS and PRP "fits very well with the South American market," and they are willing to establish a demonstration site in South America to launch the first cooperation.
Middle East Market: Strong Demand for Male Medicine and Prostate Treatment
Medical representatives from the UAE, Qatar, Turkey, and Saudi Arabia gathered to inquire about CPPS (chronic prostatitis pain syndrome), treatment options for male medicine, the feasibility of implementing consumable-based treatments across multiple clinics, and the rapid introduction of high-end self-pay treatment courses.
Several Middle Eastern clients have already requested to return on the second or third day of the exhibition for further discussions.
European Distributors: Active Negotiations, Promising Collaboration Prospects
On the first day of the exhibition, several European medical equipment companies expressed interest in collaboration. Two Italian medical equipment distributors are eager to introduce LIPUS to the local market. A young distributor from Poland was very proactive and asked for complete information to be sent to them. Spanish distributors raised professional questions about extending LIPUS applications to orthopedics and rehabilitation. Senior executives from a Croatian company directly proposed establishing a subsequent cooperation pipeline.
Overall, demand for LIPUS is far exceeding expectations.
WBL Launches a New Chapter in Global Micro-Energy Medicine Promotion
2025 is undoubtedly a key turning point for LIPUS to go global. The enthusiastic response on the first day of MEDICA signals the worldwide surge in demand for non-invasive treatments. Regenerative medicine and male health sectors are urgently looking for new technologies, urologists are willing to engage with new therapies, and distributors from multiple countries are eager to get involved in the LIPUS business.
WBL's global expansion is now officially underway. Over the next few days, WBL will engage in deeper discussions with more countries, continue to promote international multi-center clinical research, medical collaborations, and agent arrangements, contributing more innovative power to the global healthcare industry.